Knight Specialty Insurance Co. recently announced the acquisition of new stake in Bone Biologics Corporation (NASDAQ:BBLG). This fresh investment now brings its stake to 14.04% valued currently at $0.61 million. In addition, Sabby Management LLC raised its holdings by 1.24 million to 1.24 million shares.
With over 3.24 million Bone Biologics Corporation (BBLG) shares trading Tuesday and a closing price of $0.18 on the day, the dollar volume was approximately $0.58 million. The shares have shown a negative half year performance of -41.94% and its price on 05/23/23 gained nearly 9.09%. Currently, there are 14.64M common shares owned by the public and among those 8.10M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for BBLG have a consensus price objective of $4.50. The analysts have set the share’s price value over the next 12 months at a high of $6.75 and a low of $2.25. The average price target is 96.0% above its recent price level and an upside to the estimated low will see the stock gain 92.0% over that period. But an upside of 97.33% will see the stock hit the forecast high price target while median target price for the stock is $4.50.
Insiders at the company have transacted a total of 1 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 500,137 shares.
Fidelity Nasdaq Composite Index F owns 5900.0 shares of the company’s stock, all valued at over $1534.0.
Shares of Bone Biologics Corporation (NASDAQ: BBLG) opened at $0.18, up $0.01 from a prior closing price of $0.17. However, the script later moved the day high at 0.2133, up 9.09%. The company’s stock has a 5-day price change of -6.69% and -45.78% over the past three months. BBLG shares are trading -14.16% year to date (YTD), with the 12-month market performance down to -89.41% lower. It has a 12-month low price of $0.14 and touched a high of $1.97 over the same period. BBLG has an average intraday trading volume of 447.11K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.62%, -21.84%, and -65.18% respectively.
Institutional ownership of Bone Biologics Corporation (NASDAQ: BBLG) shares accounts for 0.30% of the company’s 14.64M shares outstanding. Mutual fund holders own 0.04%, while other institutional holders and individual stakeholders account for 27.53% and — respectively.
It has a market capitalization of $3.26M. The earnings-per-share (ttm) stands at -$0.17. Price movements for the stock have been influenced by the stock’s volatility, which stands at 20.24% over the week and 16.73% over the month.
Analysts forecast that Bone Biologics Corporation (BBLG) will achieve an EPS of -$0.16 for the current quarter, -$0.1 for the next quarter and -$0.47 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.23 while analysts give the company a high EPS estimate of -$0.09. Comparatively, EPS for the current quarter was -$0.07 a year ago. Earnings per share for the fiscal year are expected to increase by 63.40%, and 13.00% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 1 brokerage firm advisors rate Bone Biologics Corporation (BBLG) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Leave a Reply